Biotech Week back issues from June 2003:
Hepatitis A vaccine does not affect course of HIV.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Hepatitis A vaccination did not affect the course of HIV infection in HIV-positive patients. "The safety and immunogenicity of inactivated hepatitis A (HepA) vaccine was assessed in 133 hepatitis A virus-seronegative, human ...
Protein mimetics could lead to more successful heart surgery.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Severe spasm of blood vessels contributes to the failure of coronary bypass surgeries and to strokes following the rupture of an aneurysm in the brain. A complex signaling pathway controls relaxation in smooth muscle cells, but researchers at ...
Nonmyeloablative conditioning enables marrow-induced tolerance.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - A nonmyeloablative conditioning regimen enables the induction of transgenic tolerance through bone marrow transplantation, according to researchers in Boston. "Immunologic reactions against gene ...
HPLC/electrospray ionization MS detects choline, acetylcholine in preparations.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- GlaxoSmithKline scientists have described "a sensitive, rapid, and specific method for the detection of choline and acetylcholine in a pharmaceutical preparation." R. Dunphy and colleagues explained, "The method employs a perfluorinated ...
Newer drug has worse side effects than older drug.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Two commonly prescribed epilepsy drugs have varied cognitive side effects, report doctors from Georgetown University Medical Center. In a double-blind, randomized study, researchers looked at two drugs, valproate, released in 1978 for ...
A novel integrin antagonist induces apoptosis in angiogenic endothelial cells.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- According to a study from Canada, "Integrin-mediated cell adhesion is necessary for endothelial cell proliferation and apoptosis, which is a major determinant in tumor-induced angiogenesis. In this study, we compared two novel, structurally ...
Patented stem cell expansion technology acquired.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- A.I. Software, Inc., (ASOW) announced that it has reached an agreement with the Weitzman Institute of Science and Technion - Israel Institute of Technology to acquire the exclusive rights of stem cell expansion technology. Medical ...
Employees at pharma company rewarded for superior performance.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Abbott Laboratories (ABT) announced that 26 Abbott employees were honored with the company's chairman's award. This award is one of the company's highest honors and is given to employees who demonstrate extraordinary performance. The ...
Vaccine producer provides updates on corporate programs.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Acambis plc (ACAM) announced its results for the first quarter ended 31 March 2003. During the first quarter of 2003, there were a number of positive developments relating to our smallpox vaccine franchise. We are announcing ...
Enterotoxin H induces Valpha-specific T-cell expansion.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Staphylococcal enterotoxin H (SEH) triggers Valpha-specific T-cell expansion. SEH "is a bacterial superantigen secreted by Staphylococcus aureus," researchers in Sweden explained. "Superantigens are presented on the MHC class II and ...
Studies demonstrate potential clinical utility of siRNA in ophthalmic disease.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Acuity Pharmaceuticals, a new pharmaceutical company, and the University of Pennsylvania released research conducted by scientists affiliated with the two organizations that supports the potential therapeutic utility of siRNA in ophthalmic disease ....
Recruitment services help enroll more than 100 protocols to date.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Acurian announced that since launching AcuPatient, its Direct-to-Patient (DTP) recruitment service for the rapid enrollment of clinical trials, and AcuSite, its database service for the identification and recruitment of clinical investigators, it ...
Contrast agent assists in accurate detection of lymph node disease.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Advanced Magnetics, Inc., (AVM) and Cytogen Corp. (CYTO) announced the presentation of data showing that magnetic resonance (MR) imaging plus an investigative contrast agent (ferumoxtran-10, Combidex) helps accurately determine if testicular cancer ...
Cancer drug maker reports first quarter results, adoption of stockholder rights plan.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Allos Therapeutics, Inc., (ALTH) reported financial results for the first quarter 2003. For the 3 months ended March 31, 2003, the company reported a net loss of $7.1 million, or $0.28 per share. This compares to a net loss of $6.5 ...
Grant awarded to develop gene expression analysis for cancer.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Althea Technologies, Inc., announced that it has received a phase I Small Business Innovation Research grant from the U.S. National Institutes of Health, by way of the National Cancer Institute (NCI), to develop a new production-oriented, ...
Calcitriol launched for hypocalcemia.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- American Pharmaceutical Partners, Inc., (APPX) announced the launch of calcitriol for injection with shared 180-days of marketing exclusivity. Calcitriol, the generic equivalent of Abbott Laboratories, Inc.'s Calcijex Injection, is indicated in the ...
Glycoengineering enhances in vivo activities.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Glycoengineering enhances and prolongs the activity of protein therapeutics, according to a report from Amgen, Inc., California. "Delivery of protein therapeutics often requires frequent injections because of low activity or rapid ...
Pharmaceutical firm reports net loss of $0.34 per share.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Amylin Pharmaceuticals, Inc., (AMLN) reported a net loss of $30.8 million, or $0.34 per share, for the first quarter ended March 31, 2003, compared to a net loss of $22.1 million, or $0.30 per share, for the same period in 2002. The ...
Biotech company reports results in line with guidance for first quarter.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Array BioPharma, Inc., (ARRY) reported financial results for the third quarter of fiscal 2003, ended March 31, 2003. During the third quarter of fiscal 2003, Array reported total revenue of $8.0 million, down 16% from $9.5 million during ...
Utah clinical reference lab announces sublicense agreement with InVivoScribe.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- ARUP Laboratories, Inc., (Associated Regional and University Pathologists, Inc.), a Utah-based clinical reference laboratory, announced that it has secured a sublicense from InVivoScribe Technologies to several dominant U.S. patents. ...
Iressa approved by FDA.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- AstraZeneca Pharmaceuticals (AZN) announced that the U.S. Food and Drug Administration (FDA) has granted approval for Iressa (gefitinib) for the treatment of advanced non-small-cell lung cancer (NSCLC). The regulatory package for Iressa ...
NIH grant awarded to generate antibodies to CMV; 1Q finances reported.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Avanir Pharmaceuticals (AVN) announced it has been awarded a grant from the U.S. National Institutes of Health (NIH) under its phase I Small Business Innovation Research (SBIR) program. The company also reported on its quarterly performance. ...
Lantus receives FDA approval for flexible administration.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Aventis announced that its basal insulin, Lantus, has been approved by the U.S. Food and Drug Administration for flexible administration at any time of day. Lantus is the first and only basal insulin analog that provides 24-hour glucose ...
High cholesterol and sugar diet impairs insulin sensitivity in rats.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- A cholesterol- and sucrose-rich diet promoted lipoprotein peroxidation and impaired insulin sensitivity in rats. "The effects of a diet rich in cholesterol and sucrose on lipoprotein peroxidation and insulin sensitivity were studied in ...
A new table-fixed retractor facilitates anterior odontoid screw fixation.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- A new table-fixed retractor facilitates anterior odontoid screw fixation. Investigators in the United States report on " ...a unique retraction device adapted for anterior odontoid screw placement." "A rigidly fixed tubular ...
Repetitive coulomb-controlled iontophoresis delivers medications topically.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Repetitive coulomb-controlled iontophoresis has potential to deliver topical drug therapy to the eye without the side effects that can occur with systemic delivery of nonsteroidal anti-inflammatory drugs (NSAIDS), suggest study findings. ...
New leadership promotions announced at healthcare firm.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Baxa Corporation announced key promotions in its leadership. Greg Baldwin has taken the position of chairman of the board of directors, in addition to his role as CEO. Jeff Baldwin has been promoted to president, while continuing as ...
Executive appointments announced by HRT producer.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Reinhard Franzen, the new CEO of Berlex Laboratories, Inc., the U.S. affiliate of Schering AG, Germany (SHR), announced appointments to his executive team. "Our parent company has long-term financial goals that depend on significant ...
Aldurazyme maker reports loss of $0.35 per share.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- BioMarin Pharmaceutical, Inc., (BMRN; BMRN) announced financial results for its first quarter ended March 31, 2003. The company incurred a loss of $19.7 million ($0.35 per share) in the first quarter of 2003 compared to a loss of $26.6 ...
Watkins named VP of business development at pharma company.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Paul C. Watkins, an experienced biotech and pharmaceutical executive, has been appointed VP of business development for BioMarker Pharmaceuticals, Inc. "Paul Watkins will lead our efforts to position BioMarker as a unique and significant ...
Positive phase II/III trial results reported for estradiol topical gel.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- BioSante Pharmaceuticals, Inc., (BISP) announced that an effective dose of Bio-E-Gel (estradiol topical gel) has been identified in its phase II/III clinical trial for the treatment of moderate-to-severe hot flushes in menopausal women. ...
Lawsuit filed over intellectual property.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Biolase Technology, Inc., (BLTI) filed suit against Diodem LLC on May 2, 2003, to reinforce Biolase's intellectual property position in the marketplace. Diodem, LLC is a small, recently formed entity purporting to hold some of the ...
Final repayment, cancellation of convertible debentures announced.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Biomira, Inc., (BIOM; BRA) announced that it has repaid in full the outstanding principal and interest with respect to its U.S. $15 million private financing of convertible debentures announced on October 1, 2001. The final installment ...
Richard L. Jackson joins board of cancer vaccine company.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Biomira, Inc., (BIOM) and its chairman, Eric Baker, announced the appointment of Richard L. Jackson, PhD, to its board of directors. Jackson is the principal of Jackson Associates, Inc., a biotechnology and pharmaceutical consulting firm ...
Update provided on regulatory filings for diabetes drug in Mexico.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Robert Rieveley, president of Biotech Holdings, provided an update on regulatory filings in Mexico for Sucanon, Biotech's type II diabetes drug. We are pleased to report that we have filed, as requested by the federal Board of Health in ...
Biotech company announces governance actions.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Boston Scientific Corporation (BSX) announced several actions related to the governance of the company. The company held its annual meeting of shareholders, during which John E. Pepper was elected a director, and John A. Abele, Joel L. ...
Pharmaceutical company to list on NYSE.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Bradley Pharmaceuticals, Inc., (BPRX) announced its listing on the NYSE from the Nasdaq Stock Exchange, effective May 13, 2003. The company's shares will be traded on the NYSE under the new symbol BDY. "The New York Stock ...
Short-term treatment for sleep disorder acquired.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Bristol-Myers Squibb Company (BMY) announced that its subsidiary Mead Johnson & Company has signed a purchase agreement with OPR Development, L.P. to acquire Cafcit (caffeine citrate) Injection and Oral Suspension, the only drug approved by the ...
Development program to develop water soluble polymer technology.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Carrington Laboratories, Inc., (CARN) announced the formation of a relationship between its DelSite Biotechnologies, Inc., subsidiary and the University of Southern Mississippi (USM) to initiate a research program to develop water soluble polymer ...
Nasal vaccine delivery platform data presented at vaccine conference.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Carrington Laboratories, Inc., (CARN) announced that results of an initial study sponsored by its subsidiary DelSite Biotechnologies, Inc., were presented at the 6th Annual Conference of Vaccine Research in Arlington, Virginia. The ...
Revenue climbs 85% for drug delivery company.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Carrington Laboratories, Inc., (CARN) reported that first quarter revenues climbed nearly 85% to $6.9 million from $3.7 million a year earlier. The net loss for the quarter ended March 31, 2003, narrowed to $298,000, or 3 cents per ...
Biotech firm president, CEO express confidence in company.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Cel-Sci Corporation (CVM) reports that Cel-Sci's president Maximilian de Clara and Cel-Sci's CEO Geert Kersten have elected to take 6 months of salary in the form of company stock. This stock is restricted from sale in the open market ...
Endothelial progenitor-like cells are angiogenesis-selective gene vectors.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Endothelial progenitor-like cells are angiogenesis-selective gene vectors. According to recent research from Canada, "human and mouse proliferation-competent, bone marrow or peripheral circulation derived endothelial progenitor-like ...
Provigil maker reports product sales of $137.6M.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Cephalon, Inc., (CEPH) reported results for the first quarter of 2003, which included total revenue of $144.7 million, product sales of $137.6 million, and diluted earnings per share of $0.21. Product sales of $137.6 million for the ...
Modified gagpol fusion gene highly immunogenic in animals.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - A novel fusion of the HIV gag and pol genes is highly immunogenic in animals, researchers in California report. "Results of both natural history studies and virus challenge studies with macaques ...
Watson expands alliance with Cipla, Ltd.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Watson Pharmaceuticals, Inc., (WPI) a specialty pharmaceutical company, announced the expansion of its generic product development alliance with Cipla, Ltd. Under the terms of the expanded agreement, Cipla will develop, manufacture, and ...
Antisense transcription in the human genome may be a common occurrence.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Antisense transcription in the human genome may be a common occurrence. "An increasing number of eukaryotic genes are being found to have naturally occurring antisense transcripts. Here we study the extent of antisense transcription in ...
Method for determination of fluconazole in human plasma described.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- A bioanalytical method that uses automated sample transferring, automated liquid/liquid extraction (LLE) and hydrophilic interaction liquid chromatography-tandem mass spectrometry has been developed by Covance Laboratories Inc. scientists for the ...
Selective amplifier genes containing c-Mpl augment hematopoietic cell expansion.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Selective amplifier genes containing c-Mpl augment hematopoietic cell expansion. "We previously developed 'selective amplifier genes (SAGs)' which confer a growth advantage to transduced cells. The SAG is a chimeric gene encoding the ...
Michael Deines named vice president of marketing.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Dharmacon, Inc., a global supplier of innovative RNA and RNA-interference (RNAi) research products, announced the appointment of Michael Deines to the newly created position of vice president of marketing. Deines will lead Dharmacon's ...
Disposition of a synthetic analogue of lipid A studied in rats.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Eisai & Co. Ltd. (Japan) is developing a treatment for sepsis resulting from Gram-negative bacterial infections. Company scientists recently characterized the disposition of the compound, E5564, a lipid A analogue that potently antagonizes ...
Neurogenetics licenses a phase II AMPA/Kainate receptor.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Neurogenetics, Inc., a privately held biopharmaceutical company, announced an agreement to license and further develop a compound from Eli Lilly and Co. The compound has a unique mechanism of action and has shown efficacy in numerous ...
Clinical studies initiated for a new insulin capsule; financial results reported.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Emisphere Technologies, Inc., (EMIS) announced that it is initiating clinical testing of an oral insulin formulation in type 2 diabetic patients in the United States under an Investigational New Drug (IND) application filed with the U.S. Food and ...
Technology provider selected to deliver comprehensive infrastructure.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- eResearchTechnology, Inc., (eRT) (ERES), an e-research technology and services provider, announced that it has entered into an agreement with Endocyte, Inc., to provide an integrated technology and services solution that includes an end-to-end ...
Genomics company reports net loss of $0.03 per share.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Epoch Biosciences, Inc., (EBIO), a provider of proprietary products that accelerate genomic analysis, reported that revenues for the first quarter increased to $2.4 million compared to $2.3 million in the like period in 2002. The net ...
Commercial lab test available.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Focus Technologies announced that the company has developed a first-generation real-time PCR test designed to detect the presence of the coronavirus associated with the development of severe acute respiratory syndrome (SARS) in patients. ...
Memantine fails to demonstrate efficacy.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Forest Laboratories, Inc., (FRX) announced that a just completed pivotal placebo-controlled study of memantine in the treatment of neuropathic pain in diabetic patients had failed to demonstrate a statistically significant difference versus placebo ...
Oncology drug maker reports strong results for first quarter 2003.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- GPC Biotech AG (GPC) reported on its successful course of business for the first quarter of 2003. For the 3 months ended March 31, 2003, revenues increased 20.5% to EUR 6.1 million, compared to EUR 5.1 million for the same period in ...
Antiangiogenic drug maker has $0.04 per share loss; clinical progress updated.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Genaera Corporation (GENR) announced its financial results for the quarter ended March 31, 2003, and promising early results for the phase I-II clinical trial of its anti-angiogenic drug, squalamine, for the treatment of age-related macular ...
Kaplan named senior VP, chief financial officer at pharmaceutical firm.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Genaissance Pharmaceuticals, Inc., (GNSC) announced that it has appointed Ben D. Kaplan to the position of senior VP and chief financial officer (CFO). "Ben is an accomplished financial executive with a strong track record in the ...
$8.1M raised in private placement financing at biotech company.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Genelabs Technologies, Inc., (GNLB) announced that it has completed the sale of 8.1 million shares of its common stock to institutional and accredited investors at a price of $1.00 per share, for gross proceeds of $8.1 million. In ...
Drug fails key test.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- The biologically engineered drug Raptiva failed to effectively treat rheumatoid arthritis patients in a key experiment, its manufacturers say. The companies said they are halting further tests on patients with the disease. ...
Aerosol formulation patent accepted in New Zealand.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Generex Biotechnology Corporation (GNBT) announced that it has received a Notice of Acceptance from the Intellectual Property office of New Zealand. The patent relates to aerosol formulations for buccal and pulmonary applications. The ...
Federal district court upholds Ceftin patent.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- GlaxoSmithKline (GSK) announced that a federal judge for the United States District Court for the Northern District of Illinois in Chicago has ruled in patent litigation involving GSK's drug Ceftin (cefuroxime axetil), a member of the cephalosporin ...
Loan agreement; restructuring releases $40M of working capital.
Jun 04, 2003 ... 2003 JUN 4 - (NewsRx.com & NewsRx.net) -- Guilford Pharmaceuticals, Inc., (GLFD) announced it has entered into an $18.8 million term loan with Wachovia Bank to restructure the synthetic lease on the company's research and development facility located in Baltimore, Maryland. The ...